Literature DB >> 25319490

Increased permeability of the epithelium of middle ear cholesteatoma.

H Koizumi1, H Suzuki, T Ohbuchi, T Kitamura, K Hashida, M Nakamura.   

Abstract

OBJECTIVE: We investigated the electrical impedance of and the expressions of tight junction molecules in the cholesteatoma epithelium to provide supporting evidence for the acid lysis theory of bone resorption in middle ear cholesteatoma.
METHODS: Study subjects were patients with primary acquired middle ear cholesteatoma and those with non-cholesteatomatous chronic otitis media who underwent tympanomastoidectomy. The electrical impedance of the cholesteatoma epithelium was measured during tympanomastoidectomy by loading alternating currents of 320 Hz and 30.7 kHz. The expressions of tricellulin (MARVELD2), claudin-1 (CLDN1) and claudin-3 (CLDN3) were examined by fluorescence immunohistochemistry and quantitative reverse transcription-polymerase chain reaction.
RESULTS: The electrical impedance of the cholesteatoma epithelium was significantly lower than that of the post-auricular skin and external auditory canal skin at both 320 Hz and 30.7 kHz. Immunoreactivity for MARVELD2, CLDN1 and CLDN3 was localised mainly in the granular layer, and to lesser degree, in the horny and spinous layers in both the cholesteatoma tissue and post-auricular skin. Fluorescence intensity was moderate for MARVELD2, weak for CLDN1 and strong for CLDN3. The expressions of MARVELD2, CLDN1 and CLDN3 mRNA were significantly lower in the cholesteatoma tissue than in the post-auricular skin.
CONCLUSIONS: These results indicate the increased permeability of the cholesteatoma epithelium and suggest that this change is, at least partially, dependent on the decrease in the expressions of the tight junction molecules. This evidence supports the acid lysis hypothesis of bone resorption in cholesteatoma.
© 2014 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25319490     DOI: 10.1111/coa.12332

Source DB:  PubMed          Journal:  Clin Otolaryngol        ISSN: 1749-4478            Impact factor:   2.597


  7 in total

1.  The Altered Mucosal Barrier Function in the Duodenum Plays a Role in the Pathogenesis of Functional Dyspepsia.

Authors:  Keishi Komori; Eikichi Ihara; Yosuke Minoda; Haruei Ogino; Taisuke Sasaki; Minako Fujiwara; Yoshinao Oda; Yoshihiro Ogawa
Journal:  Dig Dis Sci       Date:  2019-01-23       Impact factor: 3.199

Review 2.  The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma.

Authors:  Shumin Xie; Xiaoli Wang; Jihao Ren; Wei Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-16       Impact factor: 2.503

3.  Osteoclasts Modulate Bone Erosion in Cholesteatoma via RANKL Signaling.

Authors:  Ryusuke Imai; Takashi Sato; Yoriko Iwamoto; Yukiko Hanada; Mika Terao; Yumi Ohta; Yasuhiro Osaki; Takao Imai; Tetsuo Morihana; Suzuyo Okazaki; Kazuo Oshima; Daisuke Okuzaki; Ichiro Katayama; Hidenori Inohara
Journal:  J Assoc Res Otolaryngol       Date:  2019-06-28

Review 4.  Gastrointestinal mucosal barrier function and diseases.

Authors:  Tadayuki Oshima; Hiroto Miwa
Journal:  J Gastroenterol       Date:  2016-04-05       Impact factor: 7.527

5.  Endoscopy-Guided Evaluation of Duodenal Mucosal Permeability in Functional Dyspepsia.

Authors:  Hideaki Ishigami; Tomoaki Matsumura; Shingo Kasamatsu; Shinsaku Hamanaka; Takashi Taida; Kenichiro Okimoto; Keiko Saito; Shoko Minemura; Daisuke Maruoka; Tomoo Nakagawa; Tatsuro Katsuno; Mai Fujie; Makoto Arai
Journal:  Clin Transl Gastroenterol       Date:  2017-04-06       Impact factor: 4.488

6.  Pattern of cholesteatomas under a scanning electron microscope - a risk factor for bone resorption.

Authors:  Agnieszka Wiatr; Katarzyna Job; Maciej Wiatr
Journal:  Acta Otorhinolaryngol Ital       Date:  2021-08       Impact factor: 2.124

7.  Identification of altered protein abundances in cholesteatoma matrix via mass spectrometry-based proteomic analysis.

Authors:  Derrick R Randall; Phillip S Park; Justin K Chau
Journal:  J Otolaryngol Head Neck Surg       Date:  2015-11-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.